Injection 8 mg and EYLEA® (aflibercept) Injection 2 mg will be presented at the Annual Meeting of the European Society of Retina Specialists (EURETINA) in Barcelona from September 19 to 22 ...

Patients in the PHOTON comparator arm received EYLEA ® (aflibercept) Injection 2 mg as a fixed 8-week dosing regimen (after five initial monthly doses) for 96 weeks. These patients were then able ...

EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA ® (aflibercept) Injection 2 mg dosed every 4 weeks Supplementary biologics license ...

Eylea 8 mg continued to demonstrate a favorable safety profile in the third year, consistent with the well-established safety profile of Eylea 2 mg. Long-term safety data revealed no new safety ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein ...

Digital access Digital + home delivery TSX-0.04 % ...